The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)—A University of Chicago phase II consortium trial.
 
Maha Hussain
Consulting or Advisory Role - AstraZeneca; Essa; Johnson & Johnson; Synthon
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech (Inst); Medivation (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
 
Stephanie Daignault
Consulting or Advisory Role - Augmenix
 
Przemyslaw Twardowski
Stock and Other Ownership Interests - Exelixis
Honoraria - Astellas Pharma; Bayer; Janssen; Medivation
Consulting or Advisory Role - Genentech; Medivation
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Medivation; Sanofi
Research Funding - Dendreon (Inst)
 
Costantine Albany
No Relationships to Disclose
 
Mark N. Stein
Research Funding - Advaxis; Amgen; Bavarian Nordic; Janssen; Medivation; Merck; Oncoceutics; Roche
 
Lakshmi Priya Kunju
No Relationships to Disclose
 
Javed Siddiqui
No Relationships to Disclose
 
Dan Robinson
No Relationships to Disclose
 
Rohit Mehra
Patents, Royalties, Other Intellectual Property - The University of Michigan has been issued a patent on the detection of ETS gene fusions in prostate cancer, on which R.M., is listed as co-inventor. The University of Michigan has licensed the diagnostic field of use to Gen-Probe, Inc. (Bedford, MA), whi (Inst)
 
Kathleen A. Cooney
Patents, Royalties, Other Intellectual Property - patent pending on discovery of HOXB13 as prostate cancer susceptibility gene (Inst)
 
Robert B. Montgomery
No Relationships to Disclose
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Consulting or Advisory Role - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Daniel H. Shevrin
Speakers' Bureau - Astellas Pharma; Bayer
 
Paul Gettys Corn
No Relationships to Disclose
 
Young E. Whang
Research Funding - Astellas Pharma (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Tokai Pharmaceuticals (Inst)
 
David C. Smith
Research Funding - Agensys (Inst); Aragon Pharmaceuticals (Inst); Atterocor (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); Eisai (Inst); Exelixis (Inst); ImClone Systems (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Millennium (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); PSMA Development Company (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Seagen (Inst); Tekmira (Inst); Teva (Inst)
 
Megan Veresh Caram
No Relationships to Disclose
 
Walter Michael Stadler
Honoraria - Bayer; CVS Caremark; Johnson & Johnson; medpacto; Merck; Sotio
Consulting or Advisory Role - Bayer; CVS Caremark; Johnson & Johnson; medpacto; Merck; Sotio
Research Funding - Active Biotech (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Other Relationship - UpToDate
 
Felix Yi-Chung Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - PFS Genomics
Consulting or Advisory Role - Celgene; GenomeDx; Medivation/Astellas
Research Funding - Celgene; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)
 
Arul M. Chinnaiyan
Stock and Other Ownership Interests - Armune Bioscience; OncoFusion Therapeutics
Honoraria - Genentech
Consulting or Advisory Role - Armune Bioscience; OncoFusion Therapeutics; Paradigm
Patents, Royalties, Other Intellectual Property - Hologic; Roche; Ventana Medical Systems